Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in immune checkpoint inhibitor-refractory non-small cell lung cancer.
Adding an immune-reactivating therapy to ongoing checkpoint inhibitors showed encouraging survival improvements in advanced lung cancer patients who had stopped responding to immunotherapy alone.
BACKGROUND: Patients with advanced non-small cell lung cancer who progress on immune checkpoint inhibitors (ICIs) face limited options and poor survival. CONCLUSIONS: In this single-arm phase 2a study, aglatimagene besadenovec plus valacyclovir with ongoing ICI was associated with systemic immune remodeling and encouraging survival.
What the study was
- Study design
- Clinical Trial (Phase 2/3)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal for immunotherapy of cancer
Why it surfaced
Matched watchlist: Novel therapeutics: immunother; scored 9/10 based on abstract-level review; design=Clinical Trial (Phase 2/3); species=human; flag=PROMISING_PRELIMINARY.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.